Houston, TXNCT07807241Now EnrollingIRB Ready

Advanced and/or Metastatic Solid Tumors Known to Express B7-H3 Clinical Trial in Houston, TX

Access cutting-edge advanced and/or metastatic solid tumors known to express b7-h3 treatment through this phase 1 clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by Myricx Pharma Limited

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access advanced and/or metastatic solid tumors known to express b7-h3 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced and/or metastatic solid tumors known to express b7-h3 treatment provided free

Apply for This Houston Location

Check if you qualify for this advanced and/or metastatic solid tumors known to express b7-h3 clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Advanced and/or Metastatic Solid Tumors Known to Express B7-H3 Study in Houston

This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3. The study will include 2 parts: * Dose-escalation (Part A) * Dose-expansion (Part B) A maximum of 120 patients may be enrolled in this study. The primary objective of the dose escalation (PART A) is to evaluate the safety and tolerability of MX006 and determine the maximum-tolerated dose (MTD) and the recommended doses for expansion (RDE) in patients with selected solid tumors; whereas the primary objective of the dose expansion (PART B) is to evaluate the safety and tolerability of MX006 at the dose level (s) recommended in Part A.

Sponsor: Myricx Pharma Limited

Who Can Participate

Inclusion Criteria

Male and female patients aged 18 years-or older at the time of signature of the informed consent form.
Patients with advanced/metastatic cancer, with measurable disease as determined by RECIST v1.1 or the Prostate Cancer Clinical Trials Working Group 3 (for mCRPC only) as per Investigator discretion. Note: Patients with mCRPC can be enrolled without measurable disease but must have a minimum of 2 bone lesions and increased PSA.
Histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors in patients with relapsed or refractory solid tumors known to express B7-H3 who have failed available standard therapy or who are not candidates for standard therapy.
Has adequate bone marrow and organ function within 7 days before the start of study
Has an adequate treatment washout period prior to start of study treatment, defined as:
Major surgery: ≥4 weeks (or 2 weeks for low-invasive cases \[e.g., colostomy\]). Note: major surgery is defined for example as a surgical procedure that is complex, invasive (e.g., enters a body cavity), is associated with higher risk of complications, and may require general anesthesia and hospitalization.
Radiation therapy: ≥4 weeks (if palliative single site stereotactic radiation therapy, ≥2 weeks.)

Exclusion Criteria

Prior treatment with an NMT inhibitor or any antibody-drug conjugate (ADC) that delivers an NMTi payload.
Has other invasive malignancy within 2 years; prior or concurrent non-invasive malignancies (with the exception of the following: in situ carcinomas of the cervix, non-melanoma skin cancers) and/or patients with localized malignancies that were treated with curative intent (e.g., localized breast cancer) who remain disease-free and are considered low likelihood for recurrence who may be enrolled on a case-by-case basis after discussion with the Medical Monitor).
Have clinically significant cardiac disease, known congestive heart failure (New York Heart Association classes II-IV) or a serious cardiac arrhythmia requiring treatment, and/ or a known decreased cardiac ejection fraction of \< 45%. A baseline QT interval as corrected by Fridericia's formula (QTcF) \> 470 msec, a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left bundle branch block form) or an incomplete left bundle branch block based on the average of triplicate 12-lead electrocardiogram (ECG) per local read.
Received any of the following within the specified time frame prior to administration of study treatment: Any systemic agent from a previous treatment regimen or clinical study including anti-cancer chemotherapy or small molecule ≤14 days or 5 half-lives (whichever is shorter); any biologic or hormonal agent ≤28 days or 5 half-lives (whichever is shorter).
Received any of the following within the specified time frame prior to administration of study treatment: Platelet transfusion, red blood cell transfusion and/or granulocyte colony-stimulating factor administration \< 1 week prior to screening assessments. Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT07807241) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced and/or Metastatic Solid Tumors Known to Express B7-H3 Treatment Options in Houston, TX

If you're searching for advanced and/or metastatic solid tumors known to express b7-h3 treatment options in Houston, TX, this clinical trial (NCT07807241) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced advanced and/or metastatic solid tumors known to express b7-h3 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced and/or metastatic solid tumors known to express b7-h3 clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Houston, TX

See all advanced solid tumors clinical trials recruiting in Houston — not just this study.

Browse Advanced Solid Tumors Trials in Houston →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsXeroderma Pigmentosum TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX